Skip to content

Author

Yi-Zong Lee

We have 3 of 15 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

De novo minibinders targeting RH5 achieve nanomolar inhibition of blood-stage malaria replication

Malaria kills ∼600,000 people annually despite recently deployed vaccines. The parasite’s blood-stage invasion of erythrocytes, driven by the essential, non-redundant interaction between Plasmodium falciparum RH5 and erythrocyte basigin, remains a leading therapeutic target. Here, we designed de novo mini-proteins (“mi...

Jason Hsiao, Melina Shamshoum, Abhiram Chalamalasetty et al. · 0 citations
Open access Aug 2026

Single-component self-assembling protein nanoparticles displaying stabilized prefusion-closed hemagglutinin trimers for influenza vaccine development

Current influenza vaccines primarily target hemagglutinin (HA), the major viral surface glycoprotein and principal determinant of neutralizing antibody (NAb) responses. However, antigenic drift and shift, together with HA’s intrinsic metastability and low-pH sensitivity, limit broad and durable vaccine protection. Here...

Yi-Nan Zhang, Xue-Yong Zhu, Keegan Braz Gomes et al. · 0 citations
Open access Aug 2026

The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages.

Describing the genetic, structural, functional, and epitope features of 25 BD-directed nAbs isolated from HCV-infected individuals or immunized macaques underscores BD as a promising target for rational HCV vaccine design.

Fang Chen, Yen Thi Kim Nguyen, Yi-Zong Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.